| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Peter Lange | |
| Jørgen Vestbo | |||
| P2860 | cites work | Pulmonary rehabilitation for chronic obstructive pulmonary disease | Q24187999 |
| Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease | Q24193702 | ||
| Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease | Q24197989 | ||
| Physical interventions to interrupt or reduce the spread of respiratory viruses | Q24235375 | ||
| Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease | Q24236241 | ||
| The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease | Q78202198 | ||
| Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD | Q80340954 | ||
| Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations | Q81820315 | ||
| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary | Q29614970 | ||
| Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease | Q29618681 | ||
| Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials | Q33498278 | ||
| An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial | Q33861510 | ||
| Reduction of exacerbation frequency in patients with COPD after participation in a comprehensive pulmonary rehabilitation program | Q34353036 | ||
| Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy | Q34480208 | ||
| Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? | Q35140742 | ||
| Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands | Q35558157 | ||
| Azithromycin for prevention of exacerbations of COPD. | Q35564000 | ||
| Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease | Q36378698 | ||
| The role of bronchodilator treatment in the prevention of exacerbations of COPD. | Q36438669 | ||
| Prevention of exacerbations: how are we doing and can we do better? | Q36458971 | ||
| Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial | Q36632054 | ||
| Frequent Chronic Obstructive Pulmonary Disease Exacerbators: How Much Real, How Much Fictitious? | Q37776725 | ||
| Impact of exacerbations on COPD | Q37801167 | ||
| Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease | Q37828179 | ||
| Rehabilitation following hospitalization in patients with COPD: can it reduce readmissions? | Q38296042 | ||
| Inhaled corticosteroids in COPD: the clinical evidence | Q38299453 | ||
| Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study | Q43873385 | ||
| Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases | Q44135492 | ||
| Tiotropium versus salmeterol for the prevention of exacerbations of COPD. | Q44248567 | ||
| Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease | Q44304480 | ||
| Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial | Q44313160 | ||
| Personalized medicine vs guideline-based medicine | Q45004208 | ||
| Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. | Q45915556 | ||
| Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. | Q45939644 | ||
| Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. | Q46011452 | ||
| Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial | Q46649423 | ||
| Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. | Q51717201 | ||
| Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. | Q55058878 | ||
| Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD | Q55932026 | ||
| Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD | Q57955575 | ||
| Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease | Q57955820 | ||
| Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited | Q57955901 | ||
| COPD Guidelines | Q58877157 | ||
| Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease | Q58877159 | ||
| Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations | Q58877199 | ||
| The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease | Q73426347 | ||
| Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease | Q74587654 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 00011-2015 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | ERJ open research | Q27726990 |
| P1476 | title | Prevention of COPD exacerbations: medications and other controversies | |
| P478 | volume | 1 |
| Q36083119 | Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD. |
| Q50089989 | Care bundles in the management of a COPD exacerbation |
| Q51530165 | Does the Term "Deflators" Reflect More Accurately the Beneficial Effects of Long-acting Bronchodilators in COPD? |
| Q92321096 | Domiciliary high-flow treatment in patients with COPD and chronic hypoxic failure: In whom can we reduce exacerbations and hospitalizations? |
| Q42362579 | Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial |
| Q28075367 | Efficacy of tiotropium-olodaterol fixed-dose combination in COPD |
| Q28596796 | Pulmonary rehabilitation and severe exacerbations of COPD: solution or white elephant? |
| Q93377739 | The dose of inhaled corticosteroids in patients with COPD: when less is better |
| Q38641441 | When is dual bronchodilation indicated in COPD? |
Search more.